Search research articles
Contact Us
Filters
Showing results (1-10 of 48) with videos related to
Page
of 5
Sort By:
Oncoimmunology
|
September 14, 2016
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
Marina Bacac, Christian Klein, Pablo Umana
Expert Opinion on Investigational Drugs
|
August 29, 2017
Combination therapy with the type II anti-CD20 antibody obinutuzumab
Christian Klein, Marina Bacac, Pablo Umana, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 4, 2014
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity
Sylvia Herter, Martina C Birk, Christian Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
T-cell-engaging Therapy for Solid Tumors
Maria de Miguel, Pablo Umana, Ana Luiza Gomes de Morais, et al.
JACC. Case Reports
|
April 18, 2025
Giant Coronary Aneurysms
Ahmad T Safdar, Joseph Sipko, Benjamin Yang, et al.
Leukemia & Lymphoma
|
December 6, 2013
Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
Frank Herting, Thomas Friess, Sabine Bader, et al.
Journal of Chromatography. A
|
October 11, 2019
FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies
Anne Freimoser-Grundschober, Petra Rueger, Felix Fingas, et al.
Brazilian Journal of Cardiovascular Surgery
|
December 22, 2017
Hypothyroidism is a Risk Factor for Atrial Fibrillation after Coronary Artery Bypass Graft
Marisol Carreno Jaimes, Luis Alberto Arciniegas Torrado, Néstor Fernando Sandoval Reyes, et al.
Bioanalysis
|
September 2, 2016
Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I
Uwe Wessels, Alexander Poehler, Miriam Moheysen-Zadeh, et al.
European Journal of Haematology
|
March 20, 2016
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)
Frank Herting, Sylvia Herter, Thomas Friess, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 48) with videos related to
Sort By:
Page
of 5
Oncoimmunology
|
September 14, 2016
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
Marina Bacac, Christian Klein, Pablo Umana
Expert Opinion on Investigational Drugs
|
August 29, 2017
Combination therapy with the type II anti-CD20 antibody obinutuzumab
Christian Klein, Marina Bacac, Pablo Umana, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 4, 2014
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity
Sylvia Herter, Martina C Birk, Christian Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2020
T-cell-engaging Therapy for Solid Tumors
Maria de Miguel, Pablo Umana, Ana Luiza Gomes de Morais, et al.
JACC. Case Reports
|
April 18, 2025
Giant Coronary Aneurysms
Ahmad T Safdar, Joseph Sipko, Benjamin Yang, et al.
Leukemia & Lymphoma
|
December 6, 2013
Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
Frank Herting, Thomas Friess, Sabine Bader, et al.
Journal of Chromatography. A
|
October 11, 2019
FcγRIIIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies
Anne Freimoser-Grundschober, Petra Rueger, Felix Fingas, et al.
Brazilian Journal of Cardiovascular Surgery
|
December 22, 2017
Hypothyroidism is a Risk Factor for Atrial Fibrillation after Coronary Artery Bypass Graft
Marisol Carreno Jaimes, Luis Alberto Arciniegas Torrado, Néstor Fernando Sandoval Reyes, et al.
Bioanalysis
|
September 2, 2016
Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I
Uwe Wessels, Alexander Poehler, Miriam Moheysen-Zadeh, et al.
European Journal of Haematology
|
March 20, 2016
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)
Frank Herting, Sylvia Herter, Thomas Friess, et al.
Page
of 5